Valeant To Shell Out $58M To End Solodyn Pay-For-Delay MDL
Valeant Pharmaceuticals International Inc. on Wednesday said it will pay more than $58 million to end pay-for-delay litigation in Massachusetts federal court alleging subsidiary Medicis Pharmaceutical Corp. illegally kept a generic...To view the full article, register now.
Already a subscriber? Click here to view full article